İlGen Sasmaz

İlGen Sasmaz

Auto-generated profile, based on publicly available information

İlGen Sasmaz

Department of Pediatric Hematology/Oncology and Bone Marrow Transplantation Unit

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2021 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
BKbarbaros sahin karagun
barbaros sahin karagun
TATuana Akbas
Tuana Akbas
FEFatih Erbey
Fatih Erbey
ISİlGen Sasmaz
İlGen Sasmaz
BABulent Antmen
Bulent Antmen
Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is one of the most severe and life-threatening complications after hematopoietic stem cell transplantation (HSCT). Defibrotide (DF) is approved for adult and pediatric patients with VOD/SOS with renal or pulmonary dysfunction after HSCT in the United States, and for severe VOD/SOS post-HSCT in patients above 1 month of age in the European Union. Several studies have examined whether DF prophylaxis can reduce the incidence of VOD/SOS in high-risk patients. A total of 334 pediatric allogeneic HSCT were included in this study. All patients received DF at the dose of 25 mg/kg/d, from the first day of the conditioning regimen to the 30th day after transplantation for VOD/SOS prophylaxis. Seventeen patients (5.08%) developed VOD/SOS; 4 of these had moderate, while 13 had mild VOD/SOS. None of the patients were developed severe or very severe VOD/SOS. In conclusion, we showed that prophylactic intervention with DF lowered the incidence of VOD/SOS in high-risk pediatric patients.

11 July 2019 in The Journal of Pediatric Research
Verified
Journal Article
Closed access
BKBarbaros Şahin Karagün
Barbaros Şahin Karagün
ÖÖÖzlem Özgür
Özlem Özgür
IŞİlgen Şaşmaz
İlgen Şaşmaz
BABülent Antmen
Bülent Antmen
EKEmine Kocabaş
Emine Kocabaş
EAEmre Alhan
Emre Alhan